- Current report filing (8-K)
December 01 2011 - 5:15PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date Of Report (Date Of Earliest Event Reported):
November 25, 2011
NORTHWEST BIOTHERAPEUTICS, INC.
|
(Exact Name of Registrant as Specified in Its Charter)
|
DELAWARE
|
|
0-33393
|
|
94-3306718
|
(State Or Other Jurisdiction Of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814
(Address Of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code (240) 497-9024
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01 Entry into a Material Definitive Agreement.
On November 25, 2011, Northwest Biotherapeutics, Inc. (the “Registrant”) and Cognate BioServices, Inc., (“Cognate”), proceeded with implementation of the agreement dating back to September 2009 (and reported in the Registrant’s 10-Q and 10-K filings since that time) to retire debts owed by the Registrant for multiple years of contract manufacturing and related services provided by Cognate during 2008-2011. The amount of such debt that was pending for conversion into equity, covering the period through June 30, 2011, was $9.8 million. The amount converted on November 25, 2011, was $9.2 million, in exchange for the issuance of 46,000,000 newly issued shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”).
Item 3.02 Unregistered Sales of Equity Securities.
The securities described in Item 1.01 above were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act and Rule 506 of Regulation D promulgated thereunder. The agreements executed in connection with this sale contain representations to support the Company’s reasonable belief that the investor had access to information concerning the Company’s operations and financial condition, the investor acquired the securities for their own account and not with a view to the distribution thereof in the absence of an effective registration statement or an applicable exemption from registration, and that the investor was sophisticated within the meaning of Section 4(2) of the Securities Act and was an “accredited investor” (as defined by Rule 501 under the Securities Act). In addition, the issuances did not involve any public offering; the Company made no solicitation in connection with the sale other than communications with the investor; the Company obtained representations from the investor regarding their investment intent, experience and sophistication; and the investor either received or had access to adequate information about the Company in order to make an informed investment decision. At the time of their issuance, the securities will be deemed to be restricted securities for purposes of the Securities Act, and the certificates representing the securities shall bear legends to that effect. The securities may not be resold or offered in the United States without registration or an exemption from registration.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC
|
|
|
|
Dated: December 1, 2011
|
By:
|
/s/
Linda Powers
|
|
|
Linda Powers
|
|
|
Chief Executive Officer and Chairman
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2023 to Aug 2024